indication

Affective Disorders, Psychotic

Competitive landscape projected to SloMo’s launch window

as of 2026-07-01
Competitive set
4
4 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
23 events
2018
2020
2022
2024
2026
2028
2030
2032
2034
2036
2038
2040
2042
today
SloMo launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 33 trials
OwnerJohnson & Johnson
Protection2041
drugWithdrawn
Brexpiprazole (Rexulti)
US-approved 2015 · Rexulti
Phase 31 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2033
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 31 trial
OwnerAstraZeneca
Protection—
drugCompleted
Ziprasidone
US-approved 2001 · Geodon
Phase 41 trial
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—

Market size

prevalence as a range, not a number